Business Segments Caplin Point Laboratories Limited NSE India S.E.
Stocks
CAPLIPOINT
INE475E01026
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,407.80 INR | +3.29% |
|
+19.22% | +30.99% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical Formulations | 10.62B | 12.71B | 14.68B | 16.96B | 19.4B | |||||
Total Assets | 13.64B | 17.36B | 21.91B | 26.98B | 32.08B | |||||
Interest Expense | -15.9M | -7M | -7.8M | -7.8M | -6.1M | |||||
Income Tax Expense | 622M | 774M | 744M | 1.03B | 1.36B | |||||
CAPEX | -705M | -912M | -1.93B | -1.46B | -1.92B | |||||
EBT | 3.14B | 3.86B | 4.51B | 5.64B | 6.77B | |||||
D&A | 358M | 452M | 426M | 510M | 630M | |||||
Net Income | 2.42B | 3B | 3.76B | 4.57B | 5.36B |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of The World | - | - | - | - | 15.83B | |||||
Total Assets | - | - | - | - | 14.48B | |||||
EBT | - | - | - | - | 5.4B | |||||
United States of America (USA) | - | - | 2.05B | 3.05B | 3.55B | |||||
Total Assets | - | - | - | - | 5.8B | |||||
EBT | - | - | - | - | 400M | |||||
Unallocated | - | - | - | - | 964M | |||||
Total Assets | - | - | - | - | 11.8B | |||||
EBT | - | - | - | - | 964M | |||||
Latin America | - | - | 12.17B | 13.55B | - | |||||
Africa | - | - | 440M | 339M | - | |||||
Export | - | - | - | - | - | |||||
India | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
